Picture [iito] Made Without Love 650x80px
Organisation › Details

Remix Therapeutics (US)

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology platform allows us to identify patterns in RNA processing and exploit them to modulate gene expression. Our innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. *


Period Start 2020-12-08 existent
Products Industry RNA processing targeted therapeutics
  Industry 2 RNA processing reprogramming technology
Persons Person Smith, Peter (Pete) (Remix Therapeutics 202012 CSO + Co-Founder)
  Person 2 Bitterman, Kevin (Atlas Venture 2017– Partner before Polaris Partners since 2004)
Region Region Cambridge, MA
  Country United States (USA)
  Street One Kendall Square
Building 200
  City 02139 Cambridge, MA
    Address record changed: 2021-01-18
Basic data Employees n. a.
    * Document for �About Section�: Remix Therapeutics. (12/8/20). "Press Release: Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing". Cambridge, MA.
Record changed: 2022-12-27


Picture [iito] [LSE] Business Portal 650x200px

More documents for Remix Therapeutics (US)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] [LSE] Business Portal 650x300px

» top